Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Innovive Pharmaceuticals has reported encouraging results from a pilot study examining Inno-305, a Wilms tumor protein heteroclitic peptide immunotherapeutic vaccine, in patients with myeloid and thoracic neoplasms.
Subscribe to our email newsletter
Preliminary data from the pilot study suggests repeat administration with Inno-305 is well tolerated and immune response can be elicited following three vaccinations.
In the study conducted at the Memorial Sloan-Kettering Cancer Center, patients receive six vaccinations over 12 weeks with Inno-305 along with the immune adjuvant Montanide. Preliminary data indicates that a CD4 response was seen in five of six patients and a CD8 response was seen in patients with HLA-A0201.
Inno-305, also known as WT1 heteroclitic peptide immunotherapy, is unique among WT1 peptide cancer immunotherapeutics because of its ability to stimulate both CD8 and CD4 T-cells.
Steve Kelly, president and CEO of Innovive Pharmaceuticals, said: “We believe Inno-305 has the potential to elicit robust immune responses in patients with several serious cancer types including AML, CML, myelodysplastic syndrome, non small cell lung cancer and mesothelioma.”